FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010907760> ?p ?o ?g. }

• W3010907760 abstract "7134 Background: To compare the efficacy and toxicity of IP vs. non-platinum-based GV in the treatment of advanced NSCLC, we conducted a randomized phase II trial with planned cross-over to the other regimen upon disease progression (PD) after the first-line therapy. Methods: Eligibility required stage IIIb/IV NSCLC, no prior chemotherapy, measurable disease, ECOG PS 0–2, adequate organ functions, and informed consent. After stratification by gender, stage (IIIB or IV) and performance status (PS: 0–1 or 2), eligible pts were randomized to receive either IP (I 65 mg/m 2 & P30 mg/m 2 on D1 & 8 q 3 weeks) first then GV (G 900 mg/m 2 &V25 mg/m 2 on D1 & 8 q 3 weeks) upon PD (Arm A) or GV first then IP upon PD (Arm B). Results: Between 12/2003 and 06/2005, 146 pts were enrolled in either Arm A (n = 75) or Arm B (n = 71). There was no difference in gender (male: 77.3% vs. 81.7%), age (median: 58 vs. 60 yrs), PS (PS 2: 10.7% vs. 8.5%), histology (adenocarcinoma: 72.0% vs. 76.6%) and stage (IV: 88.0% vs. 87.3%). IP tended to generate more responses than GN (42.0% vs. 29.0% as first-line, 30.2% vs. 14.3% as second-line), but there was no difference in total response rate by the treatment arm (Arm A: 45.6%, B: 43.5%). During the first-line therapy, IP caused more G3+ anemia (20.0% vs. 7.1%, p = 0.048), G2/3 nausea/vomiting (41.4% vs. 12.9%, p < 0.001), G2 alopecia (35.7% vs. 10.0%, p = 0.001) than GN while pneumonitis was noted only with GN (11.4%). Toxicity profile was similar after the second-line therapy. Both arms resulted in excellent survival outcome with no significant difference between the Arm A and B (median: 16.5 mo vs. 15.1 mo, p = 0.595). Conclusions: Platinum-based IP regimen seemed to be more effective in terms of response rate. Given the overall survival data and the mild toxicity profile of GV regimen, however, either treatment sequence seems to be acceptable for the treatment of advanced metastatic NSCLC. (Supported in part by NCC grants 0210140 and 0510140). No significant financial relationships to disclose." @default.
• W3010907760 created "2020-03-23" @default.
• W3010907760 creator A5005324384 @default.
• W3010907760 creator A5006869052 @default.
• W3010907760 creator A5007927376 @default.
• W3010907760 creator A5017917345 @default.
• W3010907760 creator A5044928385 @default.
• W3010907760 creator A5053137024 @default.
• W3010907760 creator A5071037071 @default.
• W3010907760 creator A5074398899 @default.
• W3010907760 date "2006-06-20" @default.
• W3010907760 modified "2023-09-24" @default.
• W3010907760 title "Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin (IP) vs. gemcitabine/vinorelbine (GV) in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer (NSCLC)" @default.
• W3010907760 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.7134" @default.
• W3010907760 hasPublicationYear "2006" @default.
• W3010907760 type Work @default.
• W3010907760 sameAs 3010907760 @default.
• W3010907760 citedByCount "3" @default.
• W3010907760 crossrefType "journal-article" @default.
• W3010907760 hasAuthorship W3010907760A5005324384 @default.
• W3010907760 hasAuthorship W3010907760A5006869052 @default.
• W3010907760 hasAuthorship W3010907760A5007927376 @default.
• W3010907760 hasAuthorship W3010907760A5017917345 @default.
• W3010907760 hasAuthorship W3010907760A5044928385 @default.
• W3010907760 hasAuthorship W3010907760A5053137024 @default.
• W3010907760 hasAuthorship W3010907760A5071037071 @default.
• W3010907760 hasAuthorship W3010907760A5074398899 @default.
• W3010907760 hasConcept C121608353 @default.
• W3010907760 hasConcept C126322002 @default.
• W3010907760 hasConcept C143998085 @default.
• W3010907760 hasConcept C168563851 @default.
• W3010907760 hasConcept C2776256026 @default.
• W3010907760 hasConcept C2776694085 @default.
• W3010907760 hasConcept C2778239845 @default.
• W3010907760 hasConcept C2779177807 @default.
• W3010907760 hasConcept C2780258809 @default.
• W3010907760 hasConcept C2780259306 @default.
• W3010907760 hasConcept C2780350996 @default.
• W3010907760 hasConcept C2781451048 @default.
• W3010907760 hasConcept C29730261 @default.
• W3010907760 hasConcept C526805850 @default.
• W3010907760 hasConcept C71924100 @default.
• W3010907760 hasConcept C81729549 @default.
• W3010907760 hasConceptScore W3010907760C121608353 @default.
• W3010907760 hasConceptScore W3010907760C126322002 @default.
• W3010907760 hasConceptScore W3010907760C143998085 @default.
• W3010907760 hasConceptScore W3010907760C168563851 @default.
• W3010907760 hasConceptScore W3010907760C2776256026 @default.
• W3010907760 hasConceptScore W3010907760C2776694085 @default.
• W3010907760 hasConceptScore W3010907760C2778239845 @default.
• W3010907760 hasConceptScore W3010907760C2779177807 @default.
• W3010907760 hasConceptScore W3010907760C2780258809 @default.
• W3010907760 hasConceptScore W3010907760C2780259306 @default.
• W3010907760 hasConceptScore W3010907760C2780350996 @default.
• W3010907760 hasConceptScore W3010907760C2781451048 @default.
• W3010907760 hasConceptScore W3010907760C29730261 @default.
• W3010907760 hasConceptScore W3010907760C526805850 @default.
• W3010907760 hasConceptScore W3010907760C71924100 @default.
• W3010907760 hasConceptScore W3010907760C81729549 @default.
• W3010907760 hasLocation W30109077601 @default.
• W3010907760 hasOpenAccess W3010907760 @default.
• W3010907760 hasPrimaryLocation W30109077601 @default.
• W3010907760 hasRelatedWork W153283011 @default.
• W3010907760 hasRelatedWork W1550216372 @default.
• W3010907760 hasRelatedWork W2143178874 @default.
• W3010907760 hasRelatedWork W2277147199 @default.
• W3010907760 hasRelatedWork W2383259583 @default.
• W3010907760 hasRelatedWork W2411860203 @default.
• W3010907760 hasRelatedWork W2412379702 @default.
• W3010907760 hasRelatedWork W2434687370 @default.
• W3010907760 hasRelatedWork W2442673159 @default.
• W3010907760 hasRelatedWork W4242551078 @default.
• W3010907760 isParatext "false" @default.
• W3010907760 isRetracted "false" @default.
• W3010907760 magId "3010907760" @default.
• W3010907760 workType "article" @default.